Imunofan: adjunctive steroid-resistance claim — RU2404792C1
Василий Вячеславович Лебедев (RU), Василий Вячеславович Лебедев, Татьяна Владимировна Величко (RU), Татьяна Владимировна Величко · 2010 · RU2404792C1 · patent family 44057532
Published 2010-11-27.
Reported patent results
Reported findings
A reported rheumatoid-arthritis/uveitis case improved during combined treatment, with immunological changes and an eight-month remission.
Patent clinical case examples of adjunctive Imunofan in steroid-resistant inflammatory eye disease; earlier literature is cited separately.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Illustrative case: inflammatory markers | ESR 40 → 5; ocular autoantibody titer 1:512 → 1:128 | Before/after combined treatment; not a controlled comparison · After the course |
| Illustrative case: visual acuity | Right eye improved to 0.9; left eye to 0.02 | Post-treatment values; do not interpret as change scores without the baseline · After the course |
| Follow-up | Remission for more than 8 months; later relapses reported 2–3 times/year | Subsequent courses and concurrent medicines complicate attribution |
The patent also cites earlier 38% and 75% remission claims; those are background research, not a newly randomized cohort in this patent. Selected combined-care examples do not establish reversal of steroid resistance.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The patent proposes Imunofan in a method addressing resistance to glucocorticoid treatment.
An adjunctive method claim does not establish generalized immune tolerance or autoimmune disease-modifying efficacy.
- Publication
- RU2404792C1 ↗ · 2010-11-27
- Earliest priority / filing
- 2009-05-20 / 2009-05-20
- Original applicant / assignee
- Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 44057532 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent for coping with steroid resistance
Inventors: Василий Вячеславович Лебедев (RU); Василий Вячеславович Лебедев; Татьяна Владимировна Величко (RU); Татьяна Владимировна Величко.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- An adjunctive method claim does not establish generalized immune tolerance or autoimmune disease-modifying efficacy.
- The patent also cites earlier 38% and 75% remission claims; those are background research, not a newly randomized cohort in this patent. Selected combined-care examples do not establish reversal of steroid resistance.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-44057532. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Василий Вячеславович Лебедев (RU), Василий Вячеславович Лебедев, Татьяна Владимировна Величко (RU), Татьяна Владимировна Величко. Imunofan: adjunctive steroid-resistance claim — RU2404792C1 RU2404792C1 · patent family 44057532 2010.
Molekul research summary: https://molekul.io/research/patent-ru2404792c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry